As per the extended contract, the company will develop a controlled release formulation that combines the client’s optimized product candidate with their proprietary drug delivery technology, PolyActive. If
As per the agreement, Ipsen is granted two exclusive options to exclusively license Oncodesign’s LRRK2 inhibitor program with worldwide development, manufacturing and commercialization rights. Oncodesign will receive milestone
The company claims Isis’ ISIS-SMNRx is developed to compensate for the underlying genetic defect that causes SMA. As per the collaboration, Isis will receive an upfront payment of
Celsis Analytical Services provides outsourced cGMP-certified laboratory services with sample turnaround times at its laboratory operations in Edison, New Jersey and St. Louis in the US. The combined
According to NeuroGenetic the funds will be used for the development of their lead candidate, NGP 555 used to prevent AD and initiate clinical trials. NGP 555, a
Eylea (aflibercept) Injection is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD) which is a major cause of blindness in older adults. The injection secured
Xeomin was approved by the US FDA in July 2010 for the treatment of cervical dystonia in adults. The drug is believed to decrease the severity of abnormal
According to the company, its Investigational New Drug Application (IND) is now open for a Phase 2 study that follows a review of PBT2 data by the FDA
ACH-1625, a once-daily HCV protease inhibitor and an open chain, non-covalent NS3 protease inhibitor, is currently being evaluated in a Phase 2 clinical trial as a treatment for
Bepotastine besilate is a non-sedating, highly selective antagonist of the histamine H1 receptor, approved in Japan for systemic use in the treatment of allergic rhinitis. The Phase 2
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.